No­vo Nordisk inks pact for dis­cov­ery of 'mol­e­c­u­lar glues' in deal worth as much as $1.46B

No­vo Nordisk has inked an up to $1.46 bil­lion deal with the biotech Neo­morph to de­vel­op “mol­e­c­u­lar glues,” a field that’s see­ing a flur­ry of drug­mak­er and ven­ture cap­i­tal in­ter­est.

The deal comes with an undis­closed up­front pay­ment. Neo­morph is a Deer­field-backed biotech that launched in 2020 with a fo­cus on “mol­e­c­u­lar glue” de­graders. The glues link pro­teins to­geth­er in ways that don’t re­quire bind­ing pock­ets, po­ten­tial­ly open­ing the door to tar­gets once con­sid­ered “un­drug­gable.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.